MicroRNA regulation of glycoprotein B5R in oncolytic vaccinia virus reduces viral pathogenicity without impairing its antitumor efficacy

Molecular Therapy

Volumn 19, Issue 6, 2011, Pages 1107-1115

  Hikichi, Mina ^a   Kidokoro, Minoru ^b   Haraguchi, Takeshi ^c   Iba, Hideo ^c   Shida, Hisatoshi ^d   Tahara, Hideaki ^a,c   Nakamura, Takafumi ^a,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA LET 7A; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN B5R;

3' UNTRANSLATED REGION; ABSENCE OF SIDE EFFECTS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B5R GENE; CANCER REGRESSION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE DELETION; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE TARGETING; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MICROBIAL ACTIVITY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; RNA SEQUENCE; SINGLE DRUG DOSE; SUBCUTANEOUS TISSUE TUMOR; TUMOR XENOGRAFT; VACCINIA; VIRUS GENE; VIRUS REPLICATION; VIRUS VIRULENCE;

MUS; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 79957910157     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.36     Document Type: Article

References (46)

1. Parato, KA, Senger, D, Forsyth, PA and Bell, JC (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976. (Pubitemid 41766784)
2. Moss, B (2001). Poxviridae: The viruses and their replication. In: Knipe, DM, Howley, PM eds. Fields Virology. Lippincott: Philadelphia, PA, pp 2849-2883.
3. Park, BH, Hwang, T, Liu, TC, Sze, DY, Kim, JS, Kwon, HC et al. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 9: 533-542.
4. Zhang, Q, Yu, YA, Wang, E, Chen, N, Danner, RL, Munson, PJ et al. (2007). Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 67: 10038-10046. (Pubitemid 47621255)
5. Hashizume, K, Yoshikawa, H, Morita, M and Suzuki, K (1985). Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain. In: Quinnan GV, ed. Vaccinia Virus as Vectors for Vaccine Antigens. Elsevier Science: Amsterdam, pp 421-428.
6. Kenner, J, Cameron, F, Empig, C, Jobes, DV and Gurwith, M (2006). LC16m8: an attenuated smallpox vaccine. Vaccine 24: 7009-7022. (Pubitemid 46107176)
7. Saito, T, Fujii, T, Kanatani, Y, Saijo, M, Morikawa, S, Yokote, H et al. (2009). Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA 301: 1025-1033.
8. Yamaguchi, M, Kimura, M and Hirayama, M (1975). Report of the National Smallpox Vaccination Research Committee: Study of side effects, complications and their treatments. Clin Virol 3: 269-278.
9. Morikawa, S, Sakiyama, T, Hasegawa, H, Saijo, M, Maeda, A, Kurane, I et al. (2005). An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. J Virol 79: 11873-11891. (Pubitemid 41279305)
10. Takahashi-Nishimaki, F, Funahashi, S, Miki, K, Hashizume, S and Sugimoto, M (1991). Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins. Virology 181: 158-164.
11. Engelstad, M and Smith, GL (1993). The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology 194: 627-637.
12. Hollinshead, M, Rodger, G, Van Eijl, H, Law, M, Hollinshead, R, Vaux, DJ et al. (2001). Vaccinia virus utilizes microtubules for movement to the cell surface. J Cell Biol 154: 389-402. (Pubitemid 34286148)
13. Katz, E, Ward, BM, Weisberg, AS and Moss, B (2003). Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein. J Virol 77: 12266-12275. (Pubitemid 37339879)
14. Newsome, TP, Scaplehorn, N and Way, M (2004). SRC mediates a switch from microtubule-to actin-based motility of vaccinia virus. Science 306: 124-129. (Pubitemid 39451954)
15. Rietdorf, J, Ploubidou, A, Reckmann, I, Holmström, A, Frischknecht, F, Zettl, M et al. (2001). Kinesin-dependent movement on microtubules precedes actin-based motility of vaccinia virus. Nat Cell Biol 3: 992-1000. (Pubitemid 34428744)
16. Schmelz, M, Sodeik, B, Ericsson, M, Wolffe, EJ, Shida, H, Hiller, G et al. (1994). Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J Virol 68: 130-147.
17. Smith, GL, Vanderplasschen, A and Law, M (2002). The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83(Pt 12): 2915-2931. (Pubitemid 36054337)
18. Ward, BM and Moss, B (2001). Visualization of intracellular movement of vaccinia virus virions containing a green fuorescent protein-B5R membrane protein chimera. J Virol 75: 4802-4813. (Pubitemid 32381523)
19. Wolffe, EJ, Isaacs, SN and Moss, B (1993). Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. J Virol 67: 4732-4741. (Pubitemid 23215953)
20. Kidokoro, M, Tashiro, M and Shida, H (2005). Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci USA 102: 4152-4157. (Pubitemid 40388571)
21. Kuruppu, D and Tanabe, KK (2005). Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol Ther 4: 524-531. (Pubitemid 41351224)
22. Mathis, JM, Stoff-Khalili, MA and Curiel, DT (2005). Oncolytic adenoviruses-selective retargeting to tumor cells. Oncogene 24: 7775-7791. (Pubitemid 41670679)
23. Cawood, R, Chen, HH, Carroll, F, Bazan-Peregrino, M, van Rooijen, N and Seymour, LW (2009). Use of tissue-specifc microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog 5: e1000440.
24. Lee, CY, Rennie, PS and Jia, WW (2009). MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res 15: 5126-5135.
25. Edge, RE, Falls, TJ, Brown, CW, Lichty, BD, Atkins, H and Bell, JC (2008). A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specifc replication. Mol Ther 16: 1437-1443.
26. Kelly, EJ, Hadac, EM, Greiner, S and Russell, SJ (2008). Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med 14: 1278-1283.
27. Lagos-Quintana, M, Rauhut, R, Lendeckel, W and Tuschl, T (2001). Identifcation of novel genes coding for small expressed RNAs. Science 294: 853-858. (Pubitemid 33032103)
28. Zeng, Y, Yi, R and Cullen, BR (2003). MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 100: 9779-9784. (Pubitemid 37087018)
29. Lagos-Quintana, M, Rauhut, R, Yalcin, A, Meyer, J, Lendeckel, W and Tuschl, T (2002). Identifcation of tissue-specifc microRNAs from mouse. Curr Biol 12: 735-739.
30. Chen, CZ (2005). MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353: 1768-1771.
31. Sempere, LF, Christensen, M, Silahtaroglu, A, Bak, M, Heath, CV, Schwartz, G et al. (2007). Altered MicroRNA expression confned to specifc epithelial cell subpopulations in breast cancer. Cancer Res 67: 11612-11620.
32. Gramantieri, L, Ferracin, M, Fornari, F, Veronese, A, Sabbioni, S, Liu, CG et al. (2007). Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 67: 6092-6099. (Pubitemid 47037488)
33. Takamizawa, J, Konishi, H, Yanagisawa, K, Tomida, S, Osada, H, Endoh, H et al. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756. (Pubitemid 38697282)
34. Johnson, SM, Grosshans, H, Shingara, J, Byrom, M, Jarvis, R, Cheng, A et al. (2005). RAS is regulated by the let-7 microRNA family. Cell 120: 635-647. (Pubitemid 40343076)
35. Müller, DW and Bosserhoff, AK (2008). Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 27: 6698-6706.
36. Torrisani, J, Bournet, B, du Rieu, MC, Bouisson, M, Souque, A, Escourrou, J et al. (2009). let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther 20: 831-844.
37. Barnes, D, Kunitomi, M, Vignuzzi, M, Saksela, K and Andino, R (2008). Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 4: 239-248.
38. Pasquinelli, AE, Reinhart, BJ, Slack, F, Martindale, MQ, Kuroda, MI, Maller, B et al. (2000). Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408: 86-89.
39. Bell, E, Shamim, M, Whitbeck, JC, Sfyroera, G, Lambris, JD and Isaacs, SN (2004). Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325: 425-431. (Pubitemid 38902805)
40. Pütz, MM, Midgley, CM, Law, M and Smith, GL (2006). Quantifcation of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 12: 1310-1315. (Pubitemid 44706934)
41. Vanderplasschen, A, Mathew, E, Hollinshead, M, Sim, RB and Smith, GL (1998). Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci USA 95: 7544-7549. (Pubitemid 28293289)
42. Kirn, DH, Wang, Y, Liang, W, Contag, CH and Thorne, SH (2008). Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res 68: 2071-2075. (Pubitemid 351521777)
43. Brown, BD, Gentner, B, Cantore, A, Colleoni, S, Amendola, M, Zingale, A et al. (2007). Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 25: 1457-1467. (Pubitemid 350233144)
44. Kelly, EJ, Hadac, EM, Cullen, BR and Russell, SJ (2010). MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference. PLoS Pathog 6: e1000820.
45. Czauderna, F, Santel, A, Hinz, M, Fechtner, M, Durieux, B, Fisch, G et al. (2003). Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res 31: e127.
46. Haraguchi, T, Ozaki, Y and Iba, H (2009). Vectors expressing effcient RNA decoys achieve the long-term suppression of specifc microRNA activity in mammalian cells. Nucleic Acids Res 37: e43